{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:01:14Z","timestamp":1775667674625,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"Supplement_B","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The choice of the best antithrombotic strategy after transcatheter aortic valve implantation (TAVI) must be based on the careful balance between the ischaemic risk and the bleeding risk and on the evaluation of some concomitant conditions, such as atrial fibrillation or coronary artery disease which may lead to the choice of anticoagulant treatment or antiplatelet therapy. Another element to consider is the possibility, albeit remote in post-TAVI patients, of thrombosis of the valve leaflets, an event whose clinical impact has yet to be fully clarified and which however appears to present a lower incidence in patients treated with anticoagulants. Recent evidence has shown that in patients who do not require anticoagulant therapy, single therapy with aspirin represents the best treatment compared to dual antiplatelet or to the addition of anticoagulant which in post-TAVI patients should be reserved only for those with a clear indication such as atrial fibrillation. It is still much debated whether in this case the choice should fall on vitamin K antagonists or on the new direct-acting anticoagulants, as the comparison studies have produced inconclusive results.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad081","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T18:03:43Z","timestamp":1682100223000},"page":"B95-B98","source":"Crossref","is-referenced-by-count":3,"title":["The temptation of anticoagulant therapy after transcatheter aortic valve implantation"],"prefix":"10.1093","volume":"25","author":[{"given":"Laura","family":"Gatto","sequence":"first","affiliation":[{"name":"Emergency Cardiology, San Giovanni Addolorata Hospital , Rome"},{"name":"Centro per la Lotta contro l'Infarto Onlus, ONLUS Foundation , Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Scalia","sequence":"additional","affiliation":[{"name":"Centro per la Lotta contro l'Infarto Onlus, ONLUS Foundation , Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2023042117455988300_suad081-B1","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1093\/eurheartj\/ehac385","article-title":"The search for optimal antithrombotic therapy in transcatheter aortic valve implantation: facts and uncertainties","volume":"43","author":"Ten Berg","year":"2022","journal-title":"Eur Heart J"},{"key":"2023042117455988300_suad081-B2","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jcin.2021.06.020","article-title":"Antithrombotic therapy after transcatheter aortic valve replacement","volume":"14","author":"Capodanno","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2023042117455988300_suad081-B3","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","article-title":"Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease","volume":"42","author":"Ten Berg","year":"2021","journal-title":"Eur Heart J"},{"key":"2023042117455988300_suad081-B4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2021","journal-title":"Eur Heart J"},{"key":"2023042117455988300_suad081-B5","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/eurheartj\/ehaa799","article-title":"Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research","volume":"42","author":"G\u00e9n\u00e9reux","year":"2021","journal-title":"Eur Heart J"},{"key":"2023042117455988300_suad081-B6","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","article-title":"Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study","volume":"389","author":"Chakravarty","year":"2017","journal-title":"Lancet"},{"key":"2023042117455988300_suad081-B7","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.jacc.2020.04.043","article-title":"Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy","volume":"75","author":"Makkar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023042117455988300_suad081-B8","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.jacc.2020.03.022","article-title":"Bioprosthetic aortic valve leaflet thickening in the Evolut low risk sub-study","volume":"75","author":"Blanke","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023042117455988300_suad081-B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvz064","article-title":"Vitamin K antagonists versus direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation","volume":"7","author":"Butt","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023042117455988300_suad081-B10","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2023042117455988300_suad081-B11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jcin.2021.05.025","article-title":"TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?","volume":"14","author":"Didier","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2023042117455988300_suad081-B12","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"2023042117455988300_suad081-B13","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"2023042117455988300_suad081-B14","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"key":"2023042117455988300_suad081-B15","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023042117455988300_suad081-B16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"2023042117455988300_suad081-B17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B95\/50061028\/suad081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B95\/50061028\/suad081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T18:03:52Z","timestamp":1682100232000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_B\/B95\/7135766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":17,"journal-issue":{"issue":"Supplement_B","published-online":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad081","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,4,1]]}}}